Cancer Research Cancer Medicine 8  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yoon, J.-H.
Right arrow Articles by Pfeifer, G. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yoon, J.-H.
Right arrow Articles by Pfeifer, G. P.
[Cancer Research 64, 7321-7328, October 15, 2004]
© 2004 American Association for Cancer Research


Regular Articles

DNA Damage, Repair, and Mutation Induction by (+)-Syn and (–)-Anti-Dibenzo[a,l]Pyrene-11,12-Diol-13,14-Epoxides in Mouse Cells

Jung-Hoon Yoon1, Ahmad Besaratinia1, Zhaohui Feng2, Moon-shong Tang2, Shantu Amin3, Andreas Luch4 and Gerd P. Pfeifer1

1 Beckman Research Institute of the City of Hope, Duarte, California; 2 New York University School of Medicine, Tuxedo, New York; 3 Institute for Cancer Prevention, Valhalla, New York; and 4 Massachusetts Institute of Technology, Cambridge, Massachusetts

Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous environmental carcinogens. PAHs are classified into bay and fjord region compounds according to structural differences in the molecule region where enzymatic epoxidation occurs. Dibenzo[a,l]pyrene (DB[a,l]P), one of the fjord region compounds, has been demonstrated to be the most carcinogenic PAH known to date. DB[a,l]P is activated to fjord region (+)-syn and (–)-anti-11,12-dihydroxy-13,14-epoxy-11,12,13,14-tetrahydrodibenzo[a,l]pyrene (DB[a,l]PDE) metabolites. In this study, we analyzed mutagenesis induced by (+)-syn- and (–)-anti-DB[a,l]PDE at the cII transgene in Big-Blue mouse cells. The mutant frequency of untreated cells (background level) was 6.53 x 10–5. This level increased 3.7-fold for 20 nmol/L, 5.3-fold for 50 nmol/L, and 7.9-fold for 100 nmol/L (+)-syn-DB[a,l]PDE, respectively. In the case of (–)-anti-DB[a,l]PDE it increased 4.5-fold for 20 nmol/L, 6.7-fold for 50 nmol/L, and 10.6-fold for 100 nmol/L, respectively, indicating that (–)-anti-DB[a,l]PDE is slightly more mutagenic than (+)-syn-DB[a,l]PDE. The mutational spectra of (+)-syn- and (–)-anti-DB[a,l]PDE were quite similar except for several hotspots, specific for either (+)-syn-DB[a,l]PDE or (–)-anti-DB[a,l]PDE. The most frequently induced mutations were A to T transversions, which were 43.9% for (+)-syn- and 38.8% for (–)-anti-DB[a,l]PDE. In addition, G to T transversions were induced significantly, at frequencies of 18.5% by (+)-syn- and 18.1% by (–)-anti-DB[a,l]PDE. Using UvrABC cleavage and ligation-mediated PCR or the terminal transferase-dependent PCR method, we have determined DB[a,l]PDE-DNA adduct formation sites and repair rates in carcinogen-exposed cells. The mutation hotspots coincided with sites of strong adduct formation, but not all of the adduct hotspots were mutational hotspots. Slow adduct removal occurred for both (+)-syn- and (–)-anti-DB[a,l]PDE adducts over a time period of up to 72 hours. The data suggest that, although the (–)-anti-isomer is slightly more mutagenic, DNA adducts of both DB[a,l]PDE stereoisomers may have similar biological properties. We discuss the implications of these findings for human cancer mutagenesis.




This article has been cited by other articles:


Home page
MutagenesisHome page
L. Anna, R. Holmila, K. Kovacs, E. Gyorffy, Z. Gyori, J. Segesdi, J. Minarovits, I. Soltesz, S. Kostic, A. Csekeo, et al.
Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary
Mutagenesis, November 1, 2009; 24(6): 475 - 480.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
A. Besaratinia, S.-i. Kim, and G. P. Pfeifer
Rapid repair of UVA-induced oxidized purines and persistence of UVB-induced dipyrimidine lesions determine the mutagenicity of sunlight in mouse cells
FASEB J, July 1, 2008; 22(7): 2379 - 2392.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
M. Malmlof, G. Paajarvi, J. Hogberg, and U. Stenius
Mdm2 as a Sensitive and Mechanistically Informative Marker for Genotoxicity Induced by Benzo[a]pyrene and Dibenzo[a,l]pyrene
Toxicol. Sci., April 1, 2008; 102(2): 232 - 240.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S.-i. Kim, G. P. Pfeifer, and A. Besaratinia
Lack of Mutagenicity of Acrolein-Induced DNA Adducts in Mouse and Human Cells
Cancer Res., December 15, 2007; 67(24): 11640 - 11647.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.